As per the latestreport published by Future Market Insights, a leading Market Research firm, the
Cell Regeneration Medicines Market is valued at US$ 30.3 Bn and is anticipated to reach the valuation of US$ 34.3 Bn by the end of 2032 bygrowing at a CAGR of 14.4%. Thecompound annual growth rate for the forecasted period is significantly higher
from the historic CAGR of 12.4%. Furthermore,the market is expected to offer an absolute dollar opportunity of US$ 96.5 Bn in the upcoming 10years.
The Therapeuticssegment generated the most revenue in the Global Cell Regeneration Medicines
Market in 2021. Revenue through this category is expected to grow at a CAGR of 16.5% during the period between 2022and 2032. This can be attributed to higher adoption of primarycell-based therapies in clinical application and their increased usage in
different therapeutic indications.
The market expansion is attributed to the introduction ofgene therapy, along with advancements in stem cell and tissue engineering. The
presence of several programmes and ongoing funding in R&D by government and
commercial entities help towards the market development. Additionally, the
regulatory approvals in this field are further clearing the present roadblocks
in the market growth.
In addition, theGlobal Cell Regeneration Medicines Market considers Oncology to be the leading
segment among Dermatology, Musculoskeletal, Immunology & Inflammation,
Oncology, Cardiovascular, Ophthalmology and Other Therapeutic Categories. It is
predicted to grow at a CAGR of 13.1% duringthe period between 2022 and 2032, while its historical CAGR stands at just 11.4%. The Oncology segments growsowing to the rising cancer patients globally, government aided cancerresearch, Cell therapies development and initiatives to reduce cancer
burden.
Key Takeawaysfrom the Market Study
- The Global Cell Regeneration Medicine Market is currently valued at US$ 30.3 Bn and is expected to reach the valuation of US$ 34.3 Bn by the end of 2022 by growing at annual growth rate of 13.2% during 2021.
- The Market for Cell Regeneration Medicine will provide an absolute dollar opportunity of US$ 96.5 Bn in the period between 2022 and 2032.
- The Therapeutics segment expected to grow at a CAGR of 16.5% and likely to remain a dominant segment in the Global Market
- The Oncology segment will be growing at a CAGR of 13.1% during the forecast period. This growth is significant as compared to its historical CAGR of just 11.4%.
- The U.S. market dominates the global market for the Cell Regeneration Medicines with a majority share of over 40% and is expected to increase at a CAGR of 14.2%.
The developing countries are predicted to be a potentialmarket with rising rates of chronic diseases, hereditary diseases, rising
geriatric population and higher demanding regions for organs and biomaterials.
However, with low awareness of Cell Regeneration Medicine and high cost of
therapies, these potential markets are difficult to capture, comments a Future Market Insightsanalyst.
Competitive Landscape
The CellRegeneration Medicine Market is driven by the Market players who are expanding
their product portfolios by highly investing in the R&D and Product
development areas. Government aids, technological developments, regulatory
approvals, mergers and acquisitions, market expansion and a diversified product
offering have all helped to maintain the environment competitive.
Some of the prominent companies in the global CellRegeneration Medicine market are AstraZeneca plc, Astellas Pharma, Inc., F.
Hoffmann-La Roche Ltd., Integra Lifesciences Corp., Cook Biotech, Inc., Bayer
AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp., Novartis AG,
GlaxoSmithKline (GSK), Baxter International, Inc., Takara Bio, Inc., etc.
The keydevelopments in the Cell Regeneration Medicine Market are:
• In January2022, AstraZeneca collaborated with Neurimmune AG and signed the licence
agreement for the development of NI006, an antibody to treat patients with
advanced ATTR-CM.
• In October2021, FDA approved the REGEN-COV on a priority basis for the treatment of Covid
19.
More InsightsAvailable
FutureMarket Insights, in its new offering, presents an unbiased analysis of the Cell
Regeneration Medicine market, presenting historical market data (2017-2021) and
forecast statistics for the period of 2022-2032.
The studyreveals essential insights on the basis of Product Type (Therapeutics, Tools,
Banks and Services), Therapeutic category (Dermatology, Musculoskeletal,
Immunology & Inflammation, Oncology, Cardiovascular, Ophthalmology and
Other Therapeutic Categories) across five regions (North America, Latin
America, Europe, Asia Pacific and Middle East & Africa).
Market SegmentsCovered in Cell Regeneration Medicine Market Analysis
- By Product Type:
- Therapeutics
- Primary Cell-based Therapeutics
- Stem Cell & Progenitor Cell-based Therapeutics
- Cell-based Immunotherapies
- Gene Therapies
- Tools
- Banks
- Services
- By TherapeuticCategory:
- Dermatology
- Musculoskeletal
- Immunology & Inflammation
- Oncology
- Cardiovascular
- Ophthalmology
- Other Therapeutic Categories
Information Source:
